Paddenstoelen zijn een onontgonnen terrein van stoffen met een bijzondere farmacologie. Vooral de polysacchariden uit paddenstoelen zijn goed bestudeerd. Die stimuleren de immuniteit, wat van pas komt in de preventie van kanker en om immuniteitsonderdrukking door kankertherapie tegen te gaan. Een aantal klinische studies, vooral rond paddenstoelen met een medicinale traditie, worden besproken.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Trefwoorden:
Verschenen in
Referenties
Wasser SP. Medicinal mushrooms in human clinical studies. Part I. Anticancer, oncoimmunological, and immunomodulatory activities: A Review. Int J Med Mushrooms. 2017;19(4):279-317
Money NP. Are mushrooms medicinal? Fungal Biol. 2016 Apr;120(4):449-453
Wasser SP. Medicinal mushroom science: Current perspectives, advances, evidences, and challenges. Biomed J. 2014 Nov-Dec;37(6):345-56
Chatterjee S, Sarma MK, Deb U et al. Mushrooms: from nutrition to mycoremediation. Environ Sci Pollut Res Int. 2017 Aug 3. doi: 10.1007/s11356-017-9826-3
de Mattos-Shipley KM, Ford KL et al. The good, the bad and the tasty: The many roles of mushrooms. Stud Mycol. 2016 Sep;85:125-157
Ben David Y, Dassa B, Borovok I et al. Ruminococcal cellulosome systems from rumen to human. Environ Microbiol. 2015 Sep;17(9):3407-26
Chen J, Seviour R. Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans. Mycol Res. 2007 Jun;111(Pt 6):635-52
Kumar V, Sinha AK et al. Dietary roles of non-starch polysaccharides in human nutrition: a review. Crit Rev Food Sci Nutr. 2012;52(10):899-935
Ruthes AC, Smiderle FR, Iacomini M. Mushroom heteropolysaccharides: A review on their sources, structure and biological effects. Carbohydr Polym. 2016 Jan 20;136:358-75
Elsayed EA, El Enshasy H et al. Mushrooms: a potential natural source of anti-inflammatory compounds for medical applications. Mediators Inflamm. 2014;2014:805841
Ivanova TS, Krupodorova TA et al. Anticancer substances of mushroom origin. Exp Oncol. 2014 Jun;36(2):58-66
Monro JA. Treatment of cancer with mushroom products. Arch Environ Health. 2003 Aug;58(8):533-7
Shin A, Kim J, Lim SY et al. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr Cancer. 2010;62(4):476-83
Kim HJ, Chang WK et al. Dietary factors and gastric cancer in Korea: a case-control study. Int J Cancer. 2002 Feb 1;97(4):531-5.
Li J, Zou L, Chen W et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One. 2014 Apr 1;9(4):e93437
Zhang M, Huang J et al. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer. 2009 Mar 15;124(6):1404-8. doi: 10.1002/ijc.24047.
Wasser SP. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol. 2011 Mar;89(5):1323-32
Okamura K, Suzuki M, Chihara T et al. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy. 1989;1(2):103-7
Noda K, Takeuchi S, Yajima A et al. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer. Jpn J Clin Oncol. 1992 Feb;22(1):17-25
Inoue M, Tanaka Y, Sugita N et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy. 1993;6(1):13-8
Mitomi T, Tsuchiya S, Iijima N et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum. 1992;35(2):123–30
Ohwada S, Ikeya T et al. Adjuvant immunotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomized controlled study. Br J Cancer 2004;90:1003–10
Alliot C. Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer. 2004;91(6):1220–1221
Oka S, Tanaka S, Yoshida S et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010;59(1):1–6
Oba K, Teramukai S, Kobayashi M et al. Efficacy of adjuvant immunochemotherapy
with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905–11
Nakano H, Namatame K, Nemoto H et al. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology. 1999 Jul-Aug;46(28):2662-8
Oba K, Kobayashi M, Matsui T et al. Individual patient based meta-analysis of Lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009;29(7):2739–45
Girard C, Bessis D. Flagellate dermatitis. Shiitake dermatitis (toxicoderma). Archives of Dermatology.2010; 146: 1301e1306
Mukai H, Wantanabe T, Ando M, Katsumata N, 2006. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Japanese Journal of Clinical Oncology 36: 808e810
Wanmuang H, Leopairut J et al. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 2007; 90:179e181
